Fig. 2

FACS analysis for double staining of CD44⁺/CD24^-/low and Aldefluor (ALDF) in MDA-MB-231, or Aldefluor in SUM159. Representative results of FACS analysis identified by CD44⁺/CD24^-/low in MDA-MB-231 (a), Aldefluor + in MDA-MB-231 (b), and Aldefluor + in SUM159 (c) treated with different doses of Cetuximab (10 μg/ml, 30 μg/ml, or 50 μg/ml) for 3 days. Proportion (%) of CD44⁺/CD24^-/low or Aldefluor + cells were determined and represented by the average of FACS analysis performed in triplicate